Our company’s R&D activities are focusing on discovery and clinical applications of molecular targeted radiotherapy. Below you can find a selection of recent publications co-authored by 3BP’s staff.

  1. Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, Mueller D, Eismant A, Almaguel F, Zboralski D, Osterkamp F, Hoehne A, Reineke U, Smerling C, Kulkarni HR. Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using 177Lu-FAP-2286: First-in-Human Results. J Nucl Med. 2021 Jun 24:jnumed.120.259192. doi: 10.2967/jnumed.120.259192. Epub ahead of print. PMID: 34168013.
  2. Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, Schibli R, Geistlich S, Schumann A, Rau T, Glatz K, Behe M, Christ ER, Wild D. Cholecystokinin-2 Receptor Agonist 177-Lutetium-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma – Results of the Lumed Phase 0a Study. J Nucl Med. 2019 Sep 13. pii: jnumed.119.233031. doi: 10.2967/jnumed.119.233031. [Epub ahead of print] PubMed PMID: 31519804.
  3. Zboralski D, Frömming A. Generation and Harnessing of Heterotypic Tumor-Stroma Spheroids to Study Cancer Immunosurveillance. Methods Mol Biol. 2019;1884:269-281. doi: 10.1007/978-1-4939-8885-3_19. PubMed PMID: 30465210.
  4. Baum RP, Singh A, Schuchardt C, Kulkarni HR, Klette I, Wiessalla S, Osterkamp F, Reineke U, Smerling C. 177-Lutetium-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results. J Nucl Med. 2018 May;59(5):809-814. doi: 10.2967/jnumed.117.193847. Epub 2017 Oct 12. PubMed PMID: 29025990
  5. Schulz J, Rohracker M, Stiebler M, Goldschmidt J, Stöber F, Noriega M, Pethe A, Lukas M, Osterkamp F, Reineke U, Höhne A, Smerling C, Amthauer H. Proof of Therapeutic Efficacy of a 177-Lutetium-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model. J Nucl Med. 2017 Jun;58(6):936-941. doi: 10.2967/jnumed.116.185140. Epub 2017 Mar 2. PubMed PMID: 28254866.
  6. Schulz J, Rohracker M, Stiebler M, Goldschmidt J, Grosser OS, Osterkamp F, Pethe A, Reineke U, Smerling C, Amthauer H. Comparative Evaluation of the Biodistribution Profiles of a Series of Nonpeptidic Neurotensin Receptor-1 Antagonists Reveals a Promising Candidate for Theranostic Applications. J Nucl Med. 2016 Jul;57(7):1120-3. doi: 10.2967/jnumed.115.170530. Epub 2016 Mar 3. PubMed PMID: 26940767.
  7. Gourni E, Mansi R, Jamous M, Waser B, Smerling C, Burian A, Buchegger F, Reubi JC, Maecke HR. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68-Gallium – and 64-Copper-labeled peptides for PET imaging. J Nucl Med. 2014 Oct;55(10):1719-25. doi: 10.2967/jnumed.114.141242. Epub 2014 Aug 21. PubMed PMID: 25146125.